代谢综合征对子宫内膜癌预后的影响：证据的系统回顾。

IF 2.6 Q3 NUTRITION & DIETETICS

Clinical nutrition ESPEN Pub Date : 2025-08-25 DOI:10.1016/j.clnesp.2025.08.011

Prodromos Koutoukoglou , Dimitra Rafailia Bakaloudi , Stavroula Chaloulakou , Michail Chourdakis

{"title":"代谢综合征对子宫内膜癌预后的影响：证据的系统回顾。","authors":"Prodromos Koutoukoglou , Dimitra Rafailia Bakaloudi , Stavroula Chaloulakou , Michail Chourdakis","doi":"10.1016/j.clnesp.2025.08.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & aims</h3><div>Endometrial cancer (EC) stands out as the 7th most frequent malignancy among women around the globe and as the most common gynecologic cancer in the developed world. Metabolic syndrome (MetS), the silent epidemic of the Western World and a major risk factor for cardiovascular disease, has already been recognized as a contributor to the genesis of EC. In this review, we aimed to examine the respective influence of MetS on the prognosis of EC.</div></div><div><h3>Methods</h3><div>A systematic literature research was conducted in PubMed, Embase and Web of Science databases up to August 19th, 2024. Observational studies (retrospective cohorts, prospective cohorts and case–control studies) were included. The endpoint of our systematic review was the impact of MetS on survival, recurrence, aggression, perioperative outcomes and generally the prognosis of EC.</div></div><div><h3>Results</h3><div>A total of 1139 studies were identified in our initial literature search. 272 duplicates were recognized and subtracted with 867 studies remaining for screening. Finally, 13 studies including 20.297 women with EC were included in our systematic review. In four studies, a worse overall survival (OS) had been reported in patients with MetS and EC compared to patients without MetS while in two studies the impact of MetS on the survival of patients with EC was found to be non-significant. A worse cancer-specific survival (CSS) in patients with MetS was reported in one study while MetS had an unfavorable impact on recurrence-free survival (RFS) in three studies. In terms of perioperative outcomes, the rates of outcomes pertinent to an increased morbidity were higher in patients with MetS while the same population suffered from a more aggressive disease compared to patients without MetS in three studies.</div></div><div><h3>Conclusions</h3><div>The coexistence of MetS could be regarded as a worse prognostic factor for patients with EC based on our findings. Intervention on prevention and treatment of MetS should be pursued but further research is needed in the field.</div></div>","PeriodicalId":10352,"journal":{"name":"Clinical nutrition ESPEN","volume":"69 ","pages":"Pages 775-784"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of metabolic syndrome on the prognosis of endometrial cancer: A systematic review of evidence\",\"authors\":\"Prodromos Koutoukoglou , Dimitra Rafailia Bakaloudi , Stavroula Chaloulakou , Michail Chourdakis\",\"doi\":\"10.1016/j.clnesp.2025.08.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background & aims</h3><div>Endometrial cancer (EC) stands out as the 7th most frequent malignancy among women around the globe and as the most common gynecologic cancer in the developed world. Metabolic syndrome (MetS), the silent epidemic of the Western World and a major risk factor for cardiovascular disease, has already been recognized as a contributor to the genesis of EC. In this review, we aimed to examine the respective influence of MetS on the prognosis of EC.</div></div><div><h3>Methods</h3><div>A systematic literature research was conducted in PubMed, Embase and Web of Science databases up to August 19th, 2024. Observational studies (retrospective cohorts, prospective cohorts and case–control studies) were included. The endpoint of our systematic review was the impact of MetS on survival, recurrence, aggression, perioperative outcomes and generally the prognosis of EC.</div></div><div><h3>Results</h3><div>A total of 1139 studies were identified in our initial literature search. 272 duplicates were recognized and subtracted with 867 studies remaining for screening. Finally, 13 studies including 20.297 women with EC were included in our systematic review. In four studies, a worse overall survival (OS) had been reported in patients with MetS and EC compared to patients without MetS while in two studies the impact of MetS on the survival of patients with EC was found to be non-significant. A worse cancer-specific survival (CSS) in patients with MetS was reported in one study while MetS had an unfavorable impact on recurrence-free survival (RFS) in three studies. In terms of perioperative outcomes, the rates of outcomes pertinent to an increased morbidity were higher in patients with MetS while the same population suffered from a more aggressive disease compared to patients without MetS in three studies.</div></div><div><h3>Conclusions</h3><div>The coexistence of MetS could be regarded as a worse prognostic factor for patients with EC based on our findings. Intervention on prevention and treatment of MetS should be pursued but further research is needed in the field.</div></div>\",\"PeriodicalId\":10352,\"journal\":{\"name\":\"Clinical nutrition ESPEN\",\"volume\":\"69 \",\"pages\":\"Pages 775-784\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical nutrition ESPEN\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405457725028979\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition ESPEN","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405457725028979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

摘要

背景与目的：子宫内膜癌（EC）是全球女性中第七大常见恶性肿瘤，也是发达国家最常见的妇科癌症。代谢综合征（MetS）是西方世界无声的流行病，也是心血管疾病的主要危险因素，已被认为是EC起源的一个贡献者。在这篇综述中，我们旨在探讨MetS对EC预后的各自影响。方法：系统查阅截至2024年8月19日的PubMed、Embase和Web of Science数据库的文献资料。包括观察性研究（回顾性队列、前瞻性队列和病例对照研究）。我们系统回顾的终点是MetS对EC的生存、复发、侵袭、围手术期结局和一般预后的影响。结果：在我们最初的文献检索中，共确定了1139项研究。确认并删除了272项重复研究，剩下867项研究用于筛选。最后，我们的系统综述纳入了13项研究，包括20.297名EC女性。在四项研究中，与没有MetS的患者相比，MetS和EC患者的总生存期（OS）更差，而在两项研究中，发现MetS对EC患者生存期的影响不显著。一项研究报告met患者的癌症特异性生存（CSS）较差，而三项研究报告met对无复发生存（RFS）有不利影响。在围手术期结果方面，在三个研究中，与没有MetS的患者相比，患有MetS的患者与发病率增加相关的结果率更高，而同一人群遭受的疾病更具侵袭性。结论：根据我们的研究结果，MetS的共存可能被认为是EC患者预后较差的因素。对MetS的预防和治疗的干预应继续进行，但需要在该领域进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of metabolic syndrome on the prognosis of endometrial cancer: A systematic review of evidence

Background & aims

Endometrial cancer (EC) stands out as the 7th most frequent malignancy among women around the globe and as the most common gynecologic cancer in the developed world. Metabolic syndrome (MetS), the silent epidemic of the Western World and a major risk factor for cardiovascular disease, has already been recognized as a contributor to the genesis of EC. In this review, we aimed to examine the respective influence of MetS on the prognosis of EC.

Methods

A systematic literature research was conducted in PubMed, Embase and Web of Science databases up to August 19th, 2024. Observational studies (retrospective cohorts, prospective cohorts and case–control studies) were included. The endpoint of our systematic review was the impact of MetS on survival, recurrence, aggression, perioperative outcomes and generally the prognosis of EC.

Results

A total of 1139 studies were identified in our initial literature search. 272 duplicates were recognized and subtracted with 867 studies remaining for screening. Finally, 13 studies including 20.297 women with EC were included in our systematic review. In four studies, a worse overall survival (OS) had been reported in patients with MetS and EC compared to patients without MetS while in two studies the impact of MetS on the survival of patients with EC was found to be non-significant. A worse cancer-specific survival (CSS) in patients with MetS was reported in one study while MetS had an unfavorable impact on recurrence-free survival (RFS) in three studies. In terms of perioperative outcomes, the rates of outcomes pertinent to an increased morbidity were higher in patients with MetS while the same population suffered from a more aggressive disease compared to patients without MetS in three studies.

Conclusions

The coexistence of MetS could be regarded as a worse prognostic factor for patients with EC based on our findings. Intervention on prevention and treatment of MetS should be pursued but further research is needed in the field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical nutrition ESPEN NUTRITION & DIETETICS-

CiteScore

4.90

自引率

3.30%

发文量

512

期刊介绍： Clinical Nutrition ESPEN is an electronic-only journal and is an official publication of the European Society for Clinical Nutrition and Metabolism (ESPEN). Nutrition and nutritional care have gained wide clinical and scientific interest during the past decades. The increasing knowledge of metabolic disturbances and nutritional assessment in chronic and acute diseases has stimulated rapid advances in design, development and clinical application of nutritional support. The aims of ESPEN are to encourage the rapid diffusion of knowledge and its application in the field of clinical nutrition and metabolism. Published bimonthly, Clinical Nutrition ESPEN focuses on publishing articles on the relationship between nutrition and disease in the setting of basic science and clinical practice. Clinical Nutrition ESPEN is available to all members of ESPEN and to all subscribers of Clinical Nutrition.